Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Obesity management interventions delivered in primary care for patients with hypertension or cardiovascular disease: a review of clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Greater weight loss correlated positively with greater reductions in blood pressure and cardiovascular risk factors regardless of which weight loss intervention was used. Dietary only interventions achieved greater initial weight loss than physical activity only interventions with the greatest weight loss occurring around 6 months. However, only lifestyle interventions that combine dietary changes and physical activity have been shown to produce significant differences in weight loss beyond 12 months. A lifestyle intervention and comprehensive metabolic risk factor management program resulted in weight loss associated with a substantial reduction in the symptom burden and symptom severity of atrial fibrillation. Motivational Interviewing (MI) was effective in bringing about long-term improvements in walking, and cholesterol levels, and was particularly effective for patients with elevated baseline levels of CVD risk factors. In overweight or obese individuals at increased cardiovascular risk, Mediterranean diets appear to be more effective than low-fat diets in inducing clinically relevant long-term changes in cardiovascular risk factors and inflammatory markers, with evidence from one study demonstrating a lasting benefit of Mediterranean diets for 2 years after the beginning of the diet. Indexing Status Subject indexing assigned by CRD MeSH Cardiovascular Diseases; Hypertension; Obesity; Primary Health Care; Weight Loss Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000228 Date abstract record published 05/03/2015 |